- Muscle spasticity associated with multiple sclerosis and spinal cord injury:
- Initially PO 2mg TDS/QID PRN
- No more than 3 doses/ 24 hours
- May increase by 2-4mg/dose every 1-4 days
- Initially PO 2mg TDS/QID PRN
- Tablet:
- 2mg
- 4mg
- Taper dose by 2-4mg/day to discontinue if prolonged, high-dose use
- Give consistently with food or on empty stomach
Alpha-2 adrenergic receptor agonist
It binds to central alpha-2 adrenergic receptors, increasing presynpatic motor neuron inhibition and reducing spasticity (centrally-acting muscle relaxant)
- Xerostomia
- Somnolence
- Asthenia
- Dizziness
- Hypotension
- Orthostatic hypotension
- Bradycardia
- UTI
- Infection
- Constipation
- Elevated ALT /AST
- Vomiting
- Speech disturbance
- Urinary frequency
- Blurred vision
- Flu syndrome
- Dyskinesia
- Nervousness
- Pharyngitis
- Rhinitis
- Hallucinations
- Abrupt withdrawal (prolonged high-dose use)
- Ciprofloxacin
- Fluvoxamine
- Viloxazine
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Use alternative |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Relezin | 2mg | Tablet | 30’s | The United Pharma | The United Pharma |
Relezin | 4mg | Tablet | 30’s | The United Pharma | The United Pharma |
Tizigesic | 2mg | Tablet | 30’s | Unichem Labs | Europa Healthcare |
Tizigesic | 4mg | Tablet | 30’s | Unichem Labs | Europa Healthcare |